New nanotherapy could potential treat Crohn’s disease in children
A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
List view / Grid view
A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
The database could save substantial resources for those wanting to do pre-clinical studies of interventions for age-related diseases, said scientists.
Researchers have identified a new compound that improved responses to insulin and treated diabetes in obese mouse models.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
A new study shows that upregulating the activity of the ACE2 signalling pathway in kidney cancer cells enhances the effects of clinically used treatments.